Rivastigmine in Frontotemporal Dementia

Moretti, Rita; Torre, Paola; Antonello, Rodolfo M.; Cattaruzza, Tatiana; Cazzato, Giuseppe; Bava, Antonio

doi:10.2165/00002512-200421140-00003

Cited by 144 publications

(93 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…27,29,30,32 Four quality B studies noted behavioral improvement without significant results, 12,28,34,36 two studies did not observe any significant behavioral change, 26,36 one study described behavioral worsening 33 and one study did not assess this aspect. 31 On the other hand, there were conflicting results from the studies that focused on the efficacy of treatment for cognitive impairment.…”

Section: Resultsmentioning

confidence: 99%

“…Seven quality B studies did not reveal any significant changes. [26][27][28]30,32,34 However, the Bromocriptine study showed a significant improvement in the mean time of utterance as compared to the placebo, 31 and one Memantine study found a significant increase in the total score of ADAS-Cog. 35 36 Two B studies did not evaluate cognitive functions.…”

Section: Resultsmentioning

confidence: 99%

“…49,50 FTLD is definitely not a hypocholinergic dementia. 30 This might explain why anticholinesterasics did not have significant therapeutic action in three studies 25,33,51 although one quality B study found significantly improved behavior 30 and one quality A study found cognitive improvement in FTLD. 22 Idazoxan is an alfa-2-adrenergic antagonist which can modulate noradrenaline function in the frontal lobe.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Pharmacological treatment of frontotemporal lobar degeneration: systematic review

Portugal

Marinho

Laks

2011

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

Objective: To identify the therapeutic options available for treatment of cognitive and behavioral symptoms in frontotemporal lobar degeneration. Method: Systematic review using the descriptors "frontotemporal lobar degeneration" OR "frontotemporal dementia" OR "fronto-temporal dementia" OR "fronto-temporal degeneration" OR "Pick's disease" OR "Pick's atrophy" OR "semantic dementia" OR "progressive aphasia" AND "pharmacotherapy" OR "treatment" OR "efficacy" OR "effects" OR "management" was performed in the Medline and Lilacs databases. Selection criteria: Quality A -randomized clinical trials. Quality Bopen studies or reports of six or more cases. Quality C -reports of five or fewer cases. Two reviewers independently assessed the clinical studies. Information collected included diagnostic criteria used, sample size, duration, efficacy and tolerability measures used and results obtained. Results: From the 532 studies found, 29 complied with the inclusion criteria. All studies worked with a small sample, had short duration of treatment and used non-uniform measures in evaluating efficacy and tolerability. Studies showed disparate results with respect to behavior and cognition. Conclusion: There is still little, and poor, evidence available for treatment of frontotemporal lobar degeneration and studies with better methodological background are needed. Descriptors IntroductionThe clinical syndromes related to frontotemporal lobar degeneration (FTLD) are the second most common cause of pre-senile primary dementia. 1 A recent Brazilian epidemiological study found a dementia prevalence of 7.1% in individuals over

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacological treatment of frontotemporal lobar degeneration: systematic review

Portugal

Marinho

Laks

2011

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…The use of antidepressants such as trazadone seem to help stabilize the behavioral symptoms, but, unfortunately, without an impact on cognition (Lebert et al 2004). Similar benefi ts have been found with the cholinesterase inhibitor rivastigmine (Moretti et al 2004), and the MAO-B inhibitor selegiline (Moretti et al 2002).…”

Section: Treatmentmentioning

confidence: 86%

A review on primary progressive aphasia

Léger

Johnson²

2008

NDT

View full text Add to dashboard Cite

Primary progressive aphasia (PPA) is a neurodegenerative disease of insidious onset presenting with progressive isolated loss of language function, without signifi cant impairment in other cognitive domains. Current diagnostic criteria require the language dysfunction to remain isolated for at least two years, and to remain the salient feature as the disease progresses, usually to involve other domains such as behavior, executive functions, and judgment. Although PPA in its early stages can usually be differentiated from probable Alzheimer's disease (PRAD) and the behavioral variant of frontotemporal lobar degeneration by the absence of signifi cant changes in memory and behavior, and the preservation of activities daily living, progression of the disease often leads to defi cits more consistent with the latter. Underlying etiologies remain heterogeneous: the neuropathological characteristics associated with frontotemporal lobar degeneration, cortocobasal degeneration, and motor neuron disease are usually found. There is a strong genetic susceptibility with affl iction of fi rst-degree relatives with similar disease in up to 40 to 50% in some series. Pathogenic mutations in genes coding for the proteins tau and progranulin have been isolated. These are leading to a better understanding of the neuropathological mechanisms and hopefully targeted disease-modifying therapy. Current therapy is limited to improving mood symptoms and targeting behavior changes as they develop. Referral to specialized centers where speech therapy, counseling, and education for both patient and caregiver are available may be helpful.

show abstract

“…Other areas where cholinesterase inhibitors may have a future role include the treatment of frontotemporal dementia (Moretti et al, 2004b), Korsakoff's syndrome (Cochrane et al, 2005), Huntington's disease (Petrikis et al, 2004) and, if evidence improves and is consistent, mild cognitive impairment (Saykin et al, 2000).…”

Section: Other Possibilitiesmentioning

confidence: 99%